Table 3.
Types of treatments and duration of therapy among patients with de novo la/mUC.
| Treatment | N (%) | Duration of Treatment, Months | ||
|---|---|---|---|---|
| Mean (SD) | Median [25th–75th Percentile] | Median (Kaplan-Meier) | ||
| 1L anti-cancer therapies | 72 (100.0) | 3.2 (2.3) | 2.8 [1.1–4.4] | 3.6 |
| Carboplatin-gemcitabine | 30 (41.7) | 3.5 (2.6) | 3.0 [1.1–4.6] | 4.2 |
| Cisplatin-gemcitabine | 29 (40.3) | 3.4 (1.9) | 3.1 [1.9–4.4] | 3.5 |
| Other a | 13 (18.1) | - | - | - |
| 2L anti-cancer therapies | 35 (100.0) | 4.2 (4.7) | 3.0 [1.6–5.0] | 4.4 |
| Pembrolizumab | 23 (65.7) | 4.4 (5.4) | 3.0 [1.4–5.0] | 5.4 |
| Other a | 12 (34.3) | - | - | - |
a Cells were suppressed due to cell sizes < 10 and due to the ability to infer certain strata < 10 based on marginal counts. Abbreviations: 1L, first line; 2 L, second line; SD, standard deviation.